Ergomed plc Anne Whitaker appointed to the Board as NED (3983O)

TIDMERGO

RNS Number : 3983O

Ergomed plc

10 June 2022

PRESS RELEASE

Anne Whitaker appointed to the Board as Non-Executive Director

Guildford, UK - 10 June 2022: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces that Anne Whitaker will join the Board as an independent Non-Executive Director following the Company's AGM later today, 10 June 2022.

Anne Whitaker has extensive life sciences industry experience, having worked across the pharmaceutical, biotech and specialty pharma sectors for the last thirty years in the US and internationally. Anne previously held a number of senior executive roles at Sanofi, GlaxoSmithKline, Bausch Health Company and Synta Pharmaceuticals, and most recently, she held the position of Chief Executive Officer, and subsequently Chairperson of Aerami Therapeutics, a private life science company. She has served as a Non-Executive Director at a number of UK-listed healthcare / pharmaceutical services companies including UDG Healthcare and Vectura Group and is currently on the board of a number of global biopharmaceutical companies.

Anne is recognised as a biopharma industry influencer, advisor and leader, having received numerous awards from PharmaVoice, WomenInc and Fierce Pharma. She holds a BSc in Chemistry and Business from the University of North Alabama.

Dr. Miroslav Reljanović, Executive Chairman of Ergomed, commented: "Anne has an excellent track record and extensive global pharmaceutical industry experience and we are delighted to have her joining the Board. I believe that her global network and deep understanding of the pharmaceutical services industry will support the continued growth and strategic development of Ergomed's CRO and PV businesses internationally."

Anne Whitaker, incoming Non-Executive Director, said: "I have witnessed Ergomed's consistent growth in recent years and I am highly excited to be joining a leading provider of specialised services to the pharmaceutical industry. I look forward to working with the Board to continue Ergomed's growth trajectory as we support customers and patients around the world."

Additional Disclosures

The following information regarding the appointment of Anne Michelle Clem Whitaker, aged 55, is disclosed under Schedule 2(g) of the AIM Rules for Companies:

 
 Current directorships and/or       Former directorships and/or partnerships 
  partnerships:                      (within the last five years): 
 Aerami Therapeutics Holdings,      Chason Dreams, LLC 
  Inc. 
 Anne Whitaker Group, LLC           Cree, Inc. 
 Bryn Pharma LLC                    ECR Pharmaceuticals Co., Inc. 
 Caladrius Biosciences, Inc.        KNOW Bio, LLC 
 Curio Digital Therapeutics, Inc.   UDG Healthcare, Plc 
 Faron Pharmaceuticals Oy           Vast Therapeutics Inc. 
 Mallinckrodt Plc*                  Vectura Group Limited 
 Nykode Therapeutics ASA            Wolfspeed, Inc. 
 OraSure Technologies Inc. 
 Trinity Life Sciences 
 

Ms Whitaker does not have any beneficial interest in the ordinary shares of the Company.

*Mallinckrodt plc filed for bankruptcy in October 2020 while facing class action litigation.

Save as set out above, no further information regarding Anne Whitaker is required to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies.

ENDS

Enquiries:

 
 Ergomed plc                                                  Tel: [phone] 
                                                                                975 
 Miroslav Reljanović (Executive 
  Chairman) 
 Richard Barfield (Chief Financial Officer) 
 Keith Byrne (Senior Vice-President, 
  Capital Markets & Strategy) 
 
 Numis (Nominated Adviser and Joint                            Tel: [phone] 
  Broker)                                                                      1000 
 Freddie Barnfield / Euan Brown (Nominated 
  Adviser) 
 James Black (Broker) 
 
  Peel Hunt LLP (Joint Broker)                                 Tel: [phone] 
  James Steel / Dr Christopher Golden                                          8900 
 
 Consilium Strategic Communications                            Tel: [phone] 
  - for UK enquiries                                                           5700 
 Chris Gardner / Matthew Neal / Angela                  [e-mail] 
  Gray 
 
 
 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAFLFLAREIAIIF

(END) Dow Jones Newswires

June 10, 2022 02:01 ET (06:01 GMT)